Drug General Information
Drug ID	D06UWF
Former ID	DIB001115
Drug Name	SOR-C13
Indication	Ovarian cancer [ICD9: 183; ICD10:C56]		Phase 1	[523872]
Company	Soricimed biopharma
Structure		Download 2D MOL
Target and Pathway
Target(s)	Transient receptor potential channel 6, subfamily V	Target Info	Inhibitor	[532294]
KEGG Pathway	Salivary secretion
	Mineral absorption
NetPath Pathway	IL2 Signaling Pathway
Pathway Interaction Database	TCR signaling in na&#xef
	Signaling events mediated by PTP1B
	TCR signaling in na&#xef
Reactome	TRP channels
WikiPathways	Vitamin D Receptor Pathway
	miR-targeted genes in lymphocytes - TarBase
References
Ref 523872	ClinicalTrials.gov (NCT01578564) Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel. U.S. National Institutes of Health.
Ref 532294	In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.